Metabolic & Cardiometabolic
GLP-1 receptor agonist decreases insulin resistance
Part of: 💊 GLP-1 Drugs
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
GLP-1 receptor agonists improve insulin resistance in PCOS (lower fasting insulin, HOMA-IR, fasting glucose).
The evidence (5)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Heise T et al 2026 · study_type: RCT | RCT | supports | moderate | Phase 1b RCT in T2D on metformin; hyperinsulinemic-euglycemic clamps at baseline and 12 weeks. Dulaglutide (GLP-1RA) arm increased clamp M-value (insulin sensitivity) by 10.4% and disposition index by 181%; combination with macupatide (GIP |
| exenatide-2022 2022 | RCT | supports | moderate | RCT long-term follow-up: exenatide vs metformin in overweight/obese infertile PCOS — exenatide improved insulin-sensitivity/weight + pregnancy outcomes. ↩ SUPERSEDED — pooled in the review above, counted once |
| beinaglutide-2023 2023 | RCT | supports | moderate | Pilot RCT (beinaglutide+metformin vs metformin, obese PCOS): GLP-1 add-on improved weight + insulin indices vs metformin monotherapy. |
| Lin S, Deng Y, Huang J, Li M, Sooranna SR, Qin M, Tan B 2025 · Scientific Reports | meta-analysis | supports | moderate | Pooled RCTs: GLP-1RAs significantly reduced fasting glucose, fasting insulin, and HOMA-IR in PCOS women. |
| Buragohain S et al 2026 · study_type: meta-analysis | meta-analysis | supports | moderate | Systematic review/meta-analysis of 18 RCTs in women with PCOS; GLP-1RAs (esp. exenatide) significantly reduced HOMA-IR vs control (SMD -0.38, 95% CI -0.61 to -0.16, p=0.001), alongside BMI reduction (MD -1.09 kg/m2). Certainty of evidence g |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.